Drug Shortage Report for HEPARIN SODIUM INJECTION, USP
| Report ID | 170881 |
| Drug Identification Number | 02264315 |
| Brand name | HEPARIN SODIUM INJECTION, USP |
| Common or Proper name | HEPARIN SODIUM INJECTION, USP |
| Company Name | FRESENIUS KABI CANADA LTD |
| Market Status | MARKETED |
| Active Ingredient(s) | HEPARIN SODIUM |
| Strength(s) | 1000UNIT |
| Dosage form(s) | SOLUTION |
| Route of administration | SUBCUTANEOUS INTRAVENOUS SUBCUTANEOUS INTRAVENOUS |
| Packaging size | 10 mL |
| ATC code | B01AB |
| ATC description | ANTITHROMBOTIC AGENTS |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | 2022-10-03 |
| Actual start date | |
| Estimated end date | 2023-01-21 |
| Actual end date | 2023-01-20 |
| Shortage status | Resolved |
| Updated date | 2023-01-26 |
| Company comments | We will also be facing a supply interruption on our Heparin Sodium Injection, USP 1 000 USP units/mL MD Vial 10 mL effective October 3, 2022 until January 21, 2023. |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 165 GALAXY BLVD, SUITE 100 TORONTO, ONTARIO CANADA M9W 0C8 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v7 | 2023-01-26 | French | Compare |
| v6 | 2023-01-26 | English | Compare |
| v5 | 2022-12-15 | French | Compare |
| v4 | 2022-12-15 | English | Compare |
| v3 | 2022-10-04 | English | Compare |
| v2 | 2022-10-02 | French | Compare |
| v1 | 2022-10-02 | English | Compare |
Showing 1 to 7 of 7